An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          Labs @ NIAMS
          NIAMS Scientific Advances
          Identification of Biomarkers in Dermatomyositis Patients with Lower Cancer Risk








NIAMS Advances


Identification of Biomarkers in Dermatomyositis Patients with Lower Cancer Risk August 25, 2022
                                CLINICAL
        Andrew Mammen, M.D., Ph.D.
                                          |
              Muscle Disease Section
                                          |
              NIAMS IRP
        Description

The clinical phenotype of dermatomyositis (DM) is uniquely influenced by specific autoantibodies. DM patients with anti-TIF1γ autoantibodies are at an increased risk of cancer. Using the PhiP-Seq (Phage Immuno-Precipitation Sequencing) technique, this study showed that anti-TIF1γ-positive DM patients with co-existing anti-Sp4 autoantibodies had significantly fewer malignancies or showed effective tumor eradication. Therefore, anti-Sp4 autoantibody could be used as biomarker in identifying anti-TIF1γ-positive DM patients who do not require aggressive cancer screening.

What is exciting about this article?

Dermatomyositis (DM) is a debilitating autoimmune muscle disease causing muscle weakness and skin rash. Approximately 70% of people with DM have a myositis-specific autoantibody that is associated with a distinct clinical phenotype. This study found that the presence of novel anti-Sp4 autoantibodies among DM patients who are positive for anti-TIF1γ autoantibodies appeared to mitigate cancer risk. This report warrants future research to determine specific biomarkers that reduce cancer risk in DM patients.

**How does this fit into the larger NIAMS portfolio?**

Dr. Mammen’s research focuses on human muscle disease as well as the basic biology of skeletal muscle regeneration. This study is an example of a productive collaboration between the Mammen lab and the Johns Hopkins Myositis Center that specializes in treating this rare family of autoimmune diseases affecting healthy muscles of the body. In the future, identifying new biomarkers to screen patients with DM for other associated clinical phenotypes will help manage this autoimmune disease better.

Grant support

AR041203
        Research Areas:
            Clinical Research
      Immunology
      Muscle Biology
                                        Reference:
            Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.

    Hosono Y, Sie B, Pinal-Fernandez I, Pak K, Mecoli CA, Casal-Dominguez M, Warner BM, Kaplan MJ, Albayda J, Danoff S, Lloyd TE, Paik JJ, Tiniakou E, Aggarwal R, Oddis CV, Moghadam-Kia S, Carmona-Rivera C, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Christopher-Stine L, Larman HB, Mammen AL
        

                    Ann Rheum Dis.
        
                    2023 Feb;
        
                    82(2).
        
                    doi: 10.1136/ard-2022-222441
                            PMID: 36008132
        Research reported in this publication was supported by the Intramural Research Program of the NIHʼs National Institute of Arthritis and Musculoskeletal and Skin Diseases.
        Previous See All Advances Next


Recent Advances
    
      Selected recent highlights of NIAMS intramural research:October 3, 2023The Transcription Factor STAT4 Controls the Fate of Cytotoxic Innate Lymphocytes
    September 26, 2023Genetic Variants of PLCG2 Cause Immune Dysregulation Through Either Increased or Decreased Function
    September 26, 2023The Microbiomes of People with Recombination-Activating Gene (RAG) Deficiency Have Distinct Features, Including Antimicrobial Resistance Signatures
    September 23, 2023Neutrophil Extracellular Traps (NETs) Trigger Pathogenic Inflammation and Bone Loss in Periodontitis
    September 22, 2023Possible Mechanism of a Rare Bone Overgrowth Disease Identified


Back to Top
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy Back to Top